Biotechnology innovation continuously advances through revolutionary therapeutic interventions addressing substantial medical gaps across multiple healthcare domains. Elafibranor has established recognition as a promising pharmaceutical candidate for treating challenging liver and metabolic pathologies, particularly non-alcoholic steatohepatitis (NASH). DelveInsight's comprehensive evaluation...